project . 2015 - 2021 . Closed

BRIDGES

Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES)
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 634935 Call for proposal: H2020-PHC-2014-two-stage
  • Funded under: H2020 | RIA Overall Budget: 6,460,000 EURFunder Contribution: 6,200,000 EUR
  • Status: Closed
  • Start Date
    01 Sep 2015
    End Date
    31 Aug 2021
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Breast cancer affects more than 360,000 women per year in the EU and causes more than 90,000 deaths. Identification of women at high risk of the disease can lead to disease prevention through intensive screening, chemoprevention or prophylactic surgery. Breast cancer risk is determined by a combination of genetic and lifestyle risk factors. The advent of next generation sequencing has opened up the opportunity for testing in many disease genes, and diagnostic gene panel testing is being introduced in many EU countries. However, the cancer risks associated with most variants in most genes are unknown. This leads to a major problem in appropriate counselling and m...
Description
Breast cancer affects more than 360,000 women per year in the EU and causes more than 90,000 deaths. Identification of women at high risk of the disease can lead to disease prevention through intensive screening, chemoprevention or prophylactic surgery. Breast cancer risk is determined by a combination of genetic and lifestyle risk factors. The advent of next generation sequencing has opened up the opportunity for testing in many disease genes, and diagnostic gene panel testing is being introduced in many EU countries. However, the cancer risks associated with most variants in most genes are unknown. This leads to a major problem in appropriate counselling and m...
Any information missing or wrong?Report an Issue